## SHIONOGI & CORP LTD.

ISIN: JP3347200002 WKN: 4507 Asset Class: Stock



### **Company Profile**

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

#### Financial figures, Fiscal year: from 01.04. to 31.03.

	2024		2023		2022	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	784,205,000,000		784,192,000,000		659,205,000,000	
Common stock capital		21,279,000,000		21,279,000,000		21,279,000,000
Fixed assets	632,713,000,000		527,608,000,000		491,396,000,000	
Equity capital of a company		1,252,561,000,000		1,121,878,000,000		993,285,000,000
Cash and cash equivalents	358,090,000,000		309,224,000,000		254,420,000,000	
Accrued liabilities		7,994,000,000		12,867,000,000		15,412,000,000
Other assets	-		-		-	
Current liabilities		133,907,000,000		158,552,000,000		124,396,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		30,447,000,000		30,106,000,000		32,656,000,000
Different income		-		-		-
Other liabilities		9,340,000,000		4,926,000,000		5,708,000,000
Total assets	1,416,918,000,000	1,416,918,000,000	1,311,800,000,000	1,311,800,000,000	1,150,601,000,000	1,150,601,000,000

#### **Balance notes**

	2024	2023	2022
Accounting standard	IFRS	IFRS	IFRS
Employees	-	5,680	5,693
Equity ratio	89.62%	87.19%	87.86%
Debt-equity ratio	11.59%	14.70%	13.82%

#### **Others**

	2024	2023	2022
Tax Expense Rate	19.02%	16.26%	10.16%

# SHIONOGI & CORP LTD.

ISIN: JP3347200002 WKN: 4507 Asset Class: Stock

Income statement			
	2024	2023	2022
Turnover	435,081,000,000	426,684,000,000	335,138,000,000
Net income	162,030,000,000	184,965,000,000	114,185,000,000
EBIT	919,860,000	1,294,386,000	758,100,000
Operating income before taxes	198,283,000,000	220,365,000,000	126,288,000,000
Cash Flow	154,284,000,000	177,867,000,000	102,068,000,000
Net interest income	44,973,000,000	4,634,000,000	-62,000,000
Research and development expenses	102,640,000,000	102,392,000,000	72,996,000,000
Income taxes	37,708,000,000	35,836,000,000	12,829,000,000
Result from investments in subsidaries, associates and other	-	-33,000,000	-20,000,000
Revenues per employee	-	450,723	353,211

<b>Board of Directors</b>	
Fumi Takatsuki	Member of Supervisory Board
Hiroshi Ozaki	Member of Supervisory Board
Keiichi Ando	Member of Supervisory Board
Takuko Sawada	Member of Supervisory Board

Members of Management Board		
Ph.D. Isao Teshirogi	Chairman of Managing Board	
John Keller	Member of Executive Committee	
Kazuhiro Hatanaka	Member of Executive Committee	
Kohji Hanasaki	Member of Executive Committee	
Noriyuki Kishida	Member of Executive Committee	
Ryuichi Kiyama	Member of Executive Committee	
Toshinobu Iwasaki	Member of Executive Committee	
Yasuyoshi Isou	Member of Executive Committee	